New nanoparticles are developed to improve cancer treatment

Researchers from the China University of Technology, Emory University and the Georgia Institute of Technology reported that they have developed a stimuli-responsive clusters of nanoparticles to improve tumor penetration and efficacy. The findings were published in the journal PNAS on March 28th.

Professor Jun Wang from China University of Science and Professor Shuming Nie from Technology and Emory University and Georgia Institute of Technology and Nie Shuming are the co-corresponding authors of this paper. Professor Jun Wang is interested in targeted cancer therapy, cancer stem cell research, nanotechnology drugs and drug delivery systems, RNA interference, nano-biomaterials. He has published more than 120 research papers in journals like Science Translational Medicine and Angew Chem Int Ed.

Cancer is a serious hazard to human health, one of the factors that undermine family and social harmony. In China, cancer has become the first cause of death in urban and rural residents, and the incidence of cancer is in a rapid increase of the number of annual cancer incidence of about 2.6 million, 1.8 million people died. In Europe and other developed countries, cancer is also ranked second in the cause of death.

Chemotherapy is traditional for the therapy of cancer, but the treatment is in advanced clinical widely used lack of selectivity. They are widely distributed in the body, especially in some normal organs and tissues may also have more distribution, reducing the use of this aspect of the drug, on the other hand also on the normal tissues and organs cause significant side effects, leading to patient tolerance reduced, weakening the therapeutic effect of the drug. In addition, long-term use of chemotherapy drugs can also cause cancer cells to chemotherapeutic drug resistance, but more difficult post-treatment. In view of this, looking for specific tumor sites, to improve the selectivity of chemotherapy drugs, it has targeted to become one of the key issues in recent years, cancer research treatment.

With the rapid development of nano-bio-technology, nano-biotechnology and disease treatment of combining the new discipline arising from nano - medicine material gradually attracted the interest of researchers. Nano drugs has become an international hotspot frontier areas of nanotechnology and biomedical research. The main objective of the nano cancer drugs is effective to treat cancer cells transferred to the Department within solid tumors. However, there are still a series of obstacles to a biological drug to reach the target cells at the nanometer.

Here the researchers report that they have developed a stimuli-responsive nanoparticles clusters, and confirmed that according to the endogenous stimulate tumor microenvironment adaptations such as size, zeta potential and drug release rate and some physicochemical properties so eventually overcome these obstacles, especially tumor infiltration may become a bottleneck.

Once iCluster accumulation at the tumor site, tumor cells outside the natural acidity will touch discharged polyamide conjugated platinum (platinum) prodrugs - amine dendrimer (diameter of about 5 nm). Such structural changes greatly improve the treatment of tumors and intracellular penetration. Internalized in the dendritic cell molecule prodrug further decomposition in cisplatin to kill cancer cells. Researchers in various refractory vivo tumor models, including the poor permeability of pancreatic cancer and metastatic cancer drug confirmed iCluster superior anti-tumor activity, demonstrating its universal and broad applicability.

You may like this: http://www.cusabio.com/ELISA-Kit/Goat-vitamin-B12-VB12-ELISA-kit-1042287.html